MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Sells 11,081 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lessened its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 42.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,731 shares of the biopharmaceutical company’s stock after selling 11,081 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Alnylam Pharmaceuticals were worth $3,468,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Jennison Associates LLC bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $61,160,000. Strategic Financial Concepts LLC bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $41,529,000. Truist Financial Corp lifted its holdings in shares of Alnylam Pharmaceuticals by 136.6% in the fourth quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company’s stock valued at $1,035,000 after purchasing an additional 2,539 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 3.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company’s stock valued at $67,464,000 after purchasing an additional 8,462 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its position in shares of Alnylam Pharmaceuticals by 13.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company’s stock valued at $4,687,000 after acquiring an additional 2,285 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the company. Bank of America increased their price target on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a “buy” rating in a research report on Friday, March 21st. Scotiabank increased their price target on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a “sector outperform” rating in a research report on Monday, March 31st. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Redburn Atlantic assumed coverage on Alnylam Pharmaceuticals in a research report on Monday, March 31st. They set a “buy” rating and a $353.00 price target for the company. Finally, Chardan Capital increased their price target on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a “buy” rating in a research report on Friday, May 2nd. One analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $319.17.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $291.86 on Tuesday. The stock has a market cap of $38.06 billion, a PE ratio of -134.50 and a beta of 0.17. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $146.79 and a fifty-two week high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The stock has a fifty day moving average of $254.72 and a 200-day moving average of $253.61.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. The business’s revenue for the quarter was up 20.2% compared to the same quarter last year. During the same period last year, the company earned ($0.16) earnings per share. Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.